20 articles
Icotrokinra, a breakthrough oral peptide targeting IL-23, demonstrates significant skin clearance in psoriasis with sustained benefits through 52 weeks.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Structural biology uncovers the exact amino acid motif causing species-specific drug failures, enabling transgenic mouse models for better P2X7 drug testing.
BNT162b2 mRNA vaccine induces special immune cells that protect against severe illness and may slow aging-related decline.
New research reveals how removing ZFP148 protein boosts CD8+ T cells' cancer-fighting ability and improves immunotherapy response.
Oral peptide targeting IL-23 receptor shows superior efficacy vs placebo and deucravacitinib in moderate-to-severe plaque psoriasis.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Breakthrough treatments targeting specific immune pathways show promise for reducing steroid dependence in EGPA patients.
A murine arthritis study finds rapamycin suppresses neuropeptide Y, linking cellular senescence to joint inflammation via SASP cytokines.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
A randomized trial shows prophylactic obinutuzumab dramatically reduces steroid-requiring cGVHD after bone marrow transplant.
A 2025 meta-analysis of 11 RCTs finds Tα1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Scientists discover unique immune peptide patterns in Behçet's disease patients that trigger harmful inflammation responses.
Master the molecular architecture of complement dysregulation in aging — from regulatory protein biochemistry to cutting-edge therapeutic targets — and understand how precision interventions can restore balance without dismantling immunity.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
New research reveals how hepatitis B virus hijacks cellular machinery to suppress interferon signaling and evade immune detection.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions — from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
A new in vitro study shows Thymosin α1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
